New drug discovery and development in India.

Area of Science:

• Pharmaceutical Sciences
• Drug Development
• Contract Research

Background:

• The Indian pharmaceutical industry has evolved significantly since the late 1990s.
• Early drug development stages in India, including custom synthesis and preclinical studies, have seen substantial improvement.
• Contract research management in India presents unique challenges and opportunities.

Purpose of the Study:

• To chronicle the development of drug discovery and development in India from 1995-1999 to the present.
• To share practical insights into managing contract research and avoiding common pitfalls.
• To assess the current landscape and future trajectory of pharmaceutical R&D in India.

Main Methods:

• Comparative analysis of drug development activities between 1995-1999 and the present.
• Review of practical experiences in managing contract research organizations (CROs).
• Examination of regulatory oversight and its impact on drug development lifecycles.

Main Results:

• Significant improvements observed in custom synthesis, animal models, bulk drug production, toxicology, and preclinical stages.
• Drug discovery efforts primarily target Western diseases, with limited focus on endemic Indian diseases.
• While some licensing deals have been secured, project termination due to safety or efficacy concerns is rare, potentially due to regulatory oversight.

Conclusions:

• The Indian pharmaceutical sector has advanced considerably in preclinical and early development stages.
• There is a critical need to reorient drug discovery towards addressing prevalent endemic diseases in India.
• Strengthening regulatory oversight is essential to ensure the safety and efficacy of drugs developed in India.